TABLE 1.
The Demographics and Baseline Characteristics of 129 Patients
| Characteristics | Total (n = 129) | Control Group (n = 59) | Lopinavir/Ritonavir Group (n = 51) | Chloroquine Group (n = 19) | P |
| Male, n (%) | 70 (54.3) | 30 (50.8) | 30 (58.8) | 10 (52.6) | 0.696 |
| Age, median (range), yrs | 33 (24–44) | 30 (23–45) | 33 (27–41) | 32 (22–50) | 0.916 |
| Comorbidities | 11 (8.5) | 4 (6.8) | 4 (7.8) | 3 (15.8) | 0.515 |
| Time from symptom onset to treatment initiation, median (range), d | 5 (3–7) | — | 5 (3–7) | 3 (3–7) | |
| Ct value of N gene, median (range) | 29.0 (24.5–31.8) | 30 (25–34) | 27.7 (28.3–30.6) | 29.5 (24.9–31.6) | 0.478 |
| Ct value of ORF1ab gene, median (range) | 28.6 (24.3–34.3) | 30 (25–35) | 27 (23.9–30.8) | 29.3 (24.9–35.9) | 0.573 |